<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195711</url>
  </required_header>
  <id_info>
    <org_study_id>ABCD blinq 2WIN</org_study_id>
    <nct_id>NCT04195711</nct_id>
  </id_info>
  <brief_title>Comparative Validation of &quot;Blinq&quot; and &quot;2WIN&quot; Vision Screeners</brief_title>
  <official_title>Comparative Validation of the Birefringent Amblyopia Screener With Isolated Small-angle Strabismus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alaska Blind Child Discovery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alaska Blind Child Discovery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      After 28 years of development, the binocular birefringence screener (&quot;blinq,&quot; &quot;Rebion&quot;) was
      commercially released. It need to be validated with AAPOS (American Association for Pediatric
      Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is
      pending.

      Adult and children pediatric and strabismus patients were screened with blinq and &quot;2WIN&quot;
      photoscreener with &quot;CR&quot; corneal reflex alignment test and then compared to confirmatory exam
      with age-appropriate determination of binocular status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a part of a new or follow-up comprehensive eye examinations, patients were screened with
      two novel objective devices according to AAPOS Uniform guidelines. Following the refractive,
      alignment and sensory testing, cycloplegic refraction was performed 30 or more minutes after
      cyclopentolate 1% drops. In cooperative patients, sensory tests including Worth 4-dot, Stereo
      Fly and &quot;PDI Check&quot; were performed to characterize binocularity. For younger patients,
      binocular function was estimated by Bruckner Test, 4- base out prism cover and the CR corneal
      reflex component of &quot;2WIN&quot; photoscreener (&quot;Adaptica,&quot; Padova Italy).

      Each patient was screened with a recently commercially released blinq screener according to
      manufacturer's recommendations. If an initial interpretation of &quot;pass&quot; or &quot;refer&quot; was not
      achieved, then repeat efforts with &quot;timed out&quot; or &quot;inconclusive&quot; were accomplished and
      results evaluated as if a &quot;refer.&quot; An example of blinq birefringent screening is shown in
      [video].

      Patients were screened with the binocular infrared autorefractor &quot;2WIN&quot; according to
      manufacturer guidelines. Refractive referral criteria were not age-stratified.

      The &quot;Rebion blinq&quot; is a unique screening method and therefore we sought to provide
      appropriate validation. In addition to non-age stratified AAPOS 2003 Uniform guidelines, we
      collected all cases characterized by constant or persistent strabismus whether large- or
      small angle employing cover test, 4 base out test, Bruckner Test and &quot;2WIN CR&quot; function. We
      did not employ any method of retinal videographic analysis of fixation instability.

      De-identified patient data recorded for sharing on study website.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Actual">November 26, 2019</completion_date>
  <primary_completion_date type="Actual">November 26, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>2003 AAPOS Uniform Amblyopia Risk Factor (ARF) Prevalence</measure>
    <time_frame>1 week</time_frame>
    <description>presence of refractive risk factor (anisometropia &gt;1.5 D, hyperopia&gt;3.5 D, astigmatism â‰¥1.5 D, myopia 3 D or more) and/or strabismus constant &gt;10 PD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocularity</measure>
    <time_frame>1 week</time_frame>
    <description>Any defective Sensory (stereopsis &gt; 200 sec arc, ocular Worth 4-Dot suppression distance and/or near) and/or objective ocular alignment (positive Bruckner Test, positive 4 prism base out test, or &quot;2WIN&quot; &quot;CR&quot; corneal reflex alignment &gt; 10 PD)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Strabismic Amblyopia</condition>
  <condition>Refractive Amblyopia</condition>
  <condition>Strabismus</condition>
  <arm_group>
    <arm_group_label>blinq screened</arm_group_label>
    <description>Patients screened by new birefringent screener</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>objective pediatric vision screen, &quot;blinq,&quot;</intervention_name>
    <description>hand-held birefringent screener for simultaneous foveation</description>
    <arm_group_label>blinq screened</arm_group_label>
    <other_name>photoscreen, birefringent screen</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in pediatric eye and adult strabismus practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Children in Pediatric Ophthalmology Practice Adult strabismus patients

        -

        Exclusion Criteria:

        patients with enucleations patients with eviscerations patients with exenterations

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Alaska Children's EYE &amp; Strabismus</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Birch EE, Subramanian V, Weakley DR. Fixation instability in anisometropic children with reduced stereopsis. J AAPOS. 2013 Jun;17(3):287-90. doi: 10.1016/j.jaapos.2013.03.011.</citation>
    <PMID>23791411</PMID>
  </reference>
  <reference>
    <citation>Gramatikov BI, Irsch K, Wu YK, Guyton DL. New pediatric vision screener, part II: electronics, software, signal processing and validation. Biomed Eng Online. 2016 Feb 4;15:15. doi: 10.1186/s12938-016-0128-7.</citation>
    <PMID>26847626</PMID>
  </reference>
  <reference>
    <citation>Arnold SL, Arnold AW, Sprano JH, Arnold RW. Performance of the 2WIN Photoscreener With &quot;CR&quot; Strabismus Estimation in High-Risk Patients. Am J Ophthalmol. 2019 Nov;207:195-203. doi: 10.1016/j.ajo.2019.04.016. Epub 2019 May 9.</citation>
    <PMID>31077668</PMID>
  </reference>
  <reference>
    <citation>Jost RM, Yanni SE, Beauchamp CL, Stager DR Sr, Stager D Jr, Dao L, Birch EE. Beyond screening for risk factors: objective detection of strabismus and amblyopia. JAMA Ophthalmol. 2014 Jul;132(7):814-20. doi: 10.1001/jamaophthalmol.2014.424.</citation>
    <PMID>24875453</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vision screening, amblyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>de-identified via website</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 month from now, ongoing</ipd_time_frame>
    <ipd_access_criteria>Study website</ipd_access_criteria>
    <ipd_url>http://www.abcd-vision.org/references/index.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

